Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place

Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.